T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$1.3B |
| 2 |
American Airlines Group
AAL
|
+$853M |
| 3 |
Intuitive Surgical
ISRG
|
+$816M |
| 4 |
Morgan Stanley
MS
|
+$681M |
| 5 |
Wynn Resorts
WYNN
|
+$622M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$1.4B |
| 2 |
eBay
EBAY
|
+$763M |
| 3 |
DISCK
Discovery, Inc. Series C Common Stock
DISCK
|
+$760M |
| 4 |
Broadcom
AVGO
|
+$757M |
| 5 |
US Bancorp
USB
|
+$686M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.64% |
| 2 | Consumer Discretionary | 13.46% |
| 3 | Financials | 12.79% |
| 4 | Industrials | 12.13% |
| 5 | Technology | 9.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GWR
376
DELISTED
Genesee & Wyoming Inc.
GWR
| $268M | 0.06% |
2,550,758
+38,110
| +2% | +$3.75M |
|
377
Vodafone
VOD
$37.1B
| $267M | 0.06% |
8,010,210
+51,269
| +0.6% | +$1.82M |
|
378
BP
BP
$111B
| $266M | 0.06% |
6,154,873
-3,179
| -0.1% | -$131K |
|
379
Valmont Industries
VMI
$9.54B
| $264M | 0.06% |
1,737,732
+206,608
| +13% | +$31.8M |
|
380
Macerich
MAC
$6.94B
| $263M | 0.06% |
3,941,423
-101,850
| -3% | -$6.65M |
|
381
Keurig Dr Pepper
KDP
$39.8B
| $261M | 0.06% |
4,460,044
-502,200
| -10% | -$28.2M |
|
382
First Horizon
FHN
$12.2B
| $260M | 0.06% |
21,923,242
-1,746,668
| -7% | -$20.4M |
|
383
Masco
MAS
$14.7B
| $257M | 0.06% |
13,199,172
-22,077
| -0.2% | -$416K |
|
384
Five Below
FIVE
$13.1B
| $256M | 0.06% |
6,424,222
+1,074,542
| +20% | +$41M |
|
385
Boston Properties
BXP
$10.8B
| $254M | 0.05% |
2,146,210
+37,120
| +2% | +$4.38M |
|
386
Pricesmart
PSMT
$5.49B
| $253M | 0.05% |
2,901,539
+35,759
| +1% | +$3.31M |
|
387
News Corp Class A
NWSA
$15.3B
| $249M | 0.05% |
13,890,225
+1,757,826
| +14% | +$30.4M |
|
388
Iron Mountain
IRM
$36.9B
| $248M | 0.05% |
7,568,923
-2,436,902
| -24% | -$66.1M |
|
|
K
389
DELISTED
Kellanova
K
| $248M | 0.05% |
4,015,281
-3,370,742
| -46% | -$211M |
|
390
Vail Resorts
MTN
$5.28B
| $243M | 0.05% |
3,151,460
-18,400
| -0.6% | -$1.29M |
|
391
Teva Pharmaceuticals
TEVA
$42.8B
| $243M | 0.05% |
+4,638,481
| New | +$237M |
|
|
SPLS
392
DELISTED
Staples Inc
SPLS
| $242M | 0.05% |
22,355,548
+1,052,200
| +5% | +$12.5M |
|
393
EOG Resources
EOG
$74.7B
| $241M | 0.05% |
2,064,604
-43,458
| -2% | -$4.57M |
|
394
Mine Safety
MSA
$7.44B
| $241M | 0.05% |
4,196,261
-157,691
| -4% | -$8.65M |
|
395
Enpro
NPO
$7.2B
| $241M | 0.05% |
3,290,058
-14,580
| -0.4% | -$1.05M |
|
396
Digital Realty Trust
DLR
$72.7B
| $241M | 0.05% |
4,126,385
-525,962
| -11% | -$29.5M |
|
|
CSC
397
DELISTED
Computer Sciences
CSC
| $240M | 0.05% |
9,003,501
-3,262,163
| -27% | -$84.4M |
|
398
Liberty Global Class A
LBTYA
$3.54B
| $239M | 0.05% |
6,542,451
-2,491,193
| -28% | -$87.3M |
|
399
Madison Square Garden
MSGS
$9.94B
| $238M | 0.05% |
5,332,705
-558,345
| -9% | -$21.9M |
|
400
Agnico Eagle Mines
AEM
$94.3B
| $235M | 0.05% |
6,132,157
+205,657
| +3% | +$6.56M |
|
Similar funds
T. Rowe Price Associates's Q2 2014 Portfolio in Review
As of Q2 2014, T. Rowe Price Associates held 2,596 positions worth $463B, up 3.9% from $445B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
T. Rowe Price Associates's Q2 2014 filing shows 97 new, 1,091 increased, 793 reduced and 67 closed positions. Its largest new stake was Teva Pharmaceuticals: 4,638,481 shares worth $243M. The largest sale was Procter & Gamble, an estimated $1.4B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2014 buy was Teva Pharmaceuticals: 4,638,481 shares worth $243M.
- T. Rowe Price Associates added most to Allergan Inc in Q2 2014, an estimated $1.3B increase.
- T. Rowe Price Associates's biggest Q2 2014 reduction was Procter & Gamble, cutting an estimated $1.4B.
- T. Rowe Price Associates fully exited Santander in Q2 2014, selling an estimated $134M.
- T. Rowe Price Associates's ten largest holdings make up 12% of its $463B portfolio in Q2 2014.
- T. Rowe Price Associates opened 97 new positions and closed 67 in Q2 2014.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $463B.
Based on T. Rowe Price Associates's 13F filing for Q2 2014, filed 14 Aug 2014.